Presidential Poster Award
-
TissueCypher® Impacts Barrett’s Esophagus Management: Actionable Risk Insights Presented at ACG
Castle Biosciences’ TissueCypher Barrett’s Esophagus test demonstrates risk insights beyond pathology, influencing clinical management, according to new data presented at ACG 2025. Research by Horvath et al. on TissueCypher received a Presidential Poster Award. Case studies showed TissueCypher identified patients at high risk for progression to esophageal cancer, prompting earlier interventions. In a rural study, the test influenced clinical management in 93% of cases, safely extending surveillance intervals for low-risk patients while ensuring timely intervention for higher-risk individuals.
